Goldman Sachs Maintains Neutral on Arcutis Biotherapeutics, Raises Price Target to $11
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Jonathan Block maintains a Neutral rating on Arcutis Biotherapeutics (ARQT) and raises the price target from $6 to $11.
February 28, 2024 | 4:21 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Goldman Sachs maintains a Neutral rating on Arcutis Biotherapeutics but raises the price target from $6 to $11.
The increase in price target from $6 to $11 by Goldman Sachs, while maintaining a Neutral rating, suggests a positive reassessment of Arcutis Biotherapeutics' valuation or future prospects. This adjustment could lead to increased investor interest and potentially a positive short-term impact on ARQT's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100